BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naito T, Uchino J, Kojima T, Matano Y, Minato K, Tanaka K, Mizukami T, Atagi S, Higashiguchi T, Muro K, Takayama K, Furuse J, Morishima E, Takiguchi T, Tamura K. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 2022. [PMID: 35195274 DOI: 10.1002/cncr.34154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol 2023;20:250-64. [PMID: 36806788 DOI: 10.1038/s41571-023-00734-5] [Reference Citation Analysis]
2 Chang VT, Sandifer C, Zhong F. GI Symptoms in Pancreatic Cancer. Clin Colorectal Cancer 2023;22:24-33. [PMID: 36623952 DOI: 10.1016/j.clcc.2022.12.002] [Reference Citation Analysis]
3 Wang CH, Tseng CY, Hsu WL, Tzen JTC. Establishment of a Cell Line Stably Expressing the Growth Hormone Secretagogue Receptor to Identify Crocin as a Ghrelin Agonist. Biomolecules 2022;12. [PMID: 36551241 DOI: 10.3390/biom12121813] [Reference Citation Analysis]
4 Takayama K, Takiguchi T, Komura N, Naito T. Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study. Cancer Med 2023;12:2918-28. [PMID: 36394148 DOI: 10.1002/cam4.5206] [Reference Citation Analysis]
5 Takayama K, Tanaka S. The Diagnosis and Treatment of Cancer Cachexia. JJLC 2022;62:180-187. [DOI: 10.2482/haigan.62.180] [Reference Citation Analysis]
6 Schuler US. On the ROMANA 1 and 2 studies on anamorelin. The Lancet Oncology 2022;23:e236. [DOI: 10.1016/s1470-2045(22)00268-6] [Reference Citation Analysis]